Medtronic is striking back in its latest battle with competitor Edwards over patents for the companies' transcatheter aortic valve replacement products. The company filed an emergency motion in a U.S. Circuit Court of Appeals to prevent an injunction against its CoreValve system from going into effect.
Add two more Abbott Laboratories diabetes products to the list of items deemed potentially deadly by the FDA. Five of the company's diabetes offerings have now been subject to the agency's most serious recall label in the past year.
Covidien is gearing up to launch its Kangaroo feeding tube in the U.S. after picking up FDA clearance for the device, which is outfitted with a camera that provides real-time images to physicians.
Irish medical device giant Covidien has purchased Florida-based New Wave Surgical for more than $100 million.
Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
On the heels of a favorable decision in federal appellate court, Varian Medical Systems agreed to pay about $35 million to the University of Pittsburgh to settle a longstanding patent dispute.
Edwards Lifesciences scored a major victory against competitor Medtronic in an ongoing patent war over the companies' transcatheter aortic valve replacement products. A U.S. District Court issued a preliminary injunction against Medtronic's CoreValve system, limiting sales of the device in the U.S.
Covidien is recalling more than 650 units of its Pipeline Embolization Device and Alligator Retrieval Device due to concerns over the coating on their delivery wires, which could delaminate and detach from the device.
Thanks to an FDA ruling, a fleet of Medtronic pacemakers and defibrillators are now cleared for use in patients with less severe heart failure.
After announcing 100 layoffs in 2013 as part of a cost-cutting strategy, AngioDynamics is rolling into the new year with revenue on the rise and a bevy of FDA nods.
Boston Scientific is ramping up neuromodulation efforts with a new clinical trial of its implantable deep brain stimulation device for patients with Parkinson's disease.
Smith & Nephew, the U.K. orthopedic giant, has agreed to pay $12 million to settle a shareholder lawsuit blocking its $1.7 billion acquisition of ArthroCare, according to a SEC filing.
Mainstay Medical is setting its sights on a €23 million ($31.9 million) IPO to support development of its implantable neuromodulation device.
Automated surgery notched a victory today, for Deerfield Management Company closed on a $27.5 million debt financing deal with OMNIlife science, provider of the FDA cleared OMNInav system.
SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans.
Abbott Laboratories has wrapped up enrollment in a 2,000-patient trial designed to win FDA approval for Absorb, its dissolvable vascular scaffold, setting sights on the world's largest market after charting success abroad.
Medical device companies with renal denervation platforms are facing yet another obstacle, as U.S. and European heart doctors are calling for a decrease or halt in the use of the devices to treat high blood pressure.
As part of its strategy to sell more products in foreign markets, Boston Scientific announced the signing of a distribution partnership agreement allowing Israel's Amos Gazit Ltd to market and sell its interventional cardiology, peripheral interventions, endoscopy and urology/women's health products.
Tendyne, a privately held medical device company focused on mitral valve repair, secured $25 million in Series C financing it will use for testing of its transcatheter mitral valve transplant system used to treat mitral regurgitation.
Venture capital outfit Split Rock Partners is planning to abandon the medical device industry, Forbes reports, looking to ditch healthcare investments and refocus on Internet services.